Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study was a randomized, controled, multicenter, phase II clinical study evaluating the
efficacy and safety of fruquintinib as a maintenance therapy following first-line treatment
for metastatic colorectal cancer. This study will include the patients with confirmed
unresectable metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer
who achieved stable disease (SD) or partial response (PR) or complete response (CR) via
palliative first-line treatment. It's expected to include 110 patients and they will be
randomly stratified at 2:1 into fruquintinib group and observation group based on whether
bevacizumab is used and the primary tumor site, using the Interactive Network Response System
(IWRS). The random No. corresponds to the respective patient. The enrollment time is expected
to be 18 months, followed up for 24 months.